Market Place
Sourcing Support
Aldeyra Therapeutics Achieves Primary Endpoint In Dry Eye Disease Trial
08 Aug 2024 //
BUSINESSWIRE
Aldeyra Schedules Call For Phase 3 Dry Eye Trial Results Of Reproxalap
07 Aug 2024 //
BUSINESSWIRE
Aldeyra Completes Enrollment In Phase 3 Reproxalap Dry Eye Disease Trial
13 Jun 2024 //
BUSINESSWIRE
Aldeyra Therapeutics: Phase 3 Trial for Reproxalap in Dry Eye
08 May 2024 //
BUSINESSWIRE
Aldeyra Receives CRL from FDA for the Reproxalap NDA for Dry Eye Disease
28 Nov 2023 //
BUSINESSWIRE
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie
01 Nov 2023 //
BUSINESSWIRE
Aldeyra sinks after FDA finds `substantive` issues in dry-eye disease filing
17 Oct 2023 //
ENDPTS
Aldeyra Therapeutics eye treatment meets late-stage study main goal
16 Jun 2023 //
REUTERS
TILT Biotherapeutics Announces Final Close of €22 Million Financing Round
07 Feb 2023 //
BUSINESSWIRE
WHO responds to The Lancet COVID-19 Commission
15 Sep 2022 //
WHO
Aldeyra Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA
14 Sep 2022 //
BUSINESSWIRE
Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
04 Aug 2022 //
SEEKING ALPHA
Aldeyra Tx Schedules Conference Call to Announce Top-Line Results of Reproxalap
11 Jul 2022 //
BUSINESSWIRE
After late-study switch, Aldeyra hails win in dry eye phase 3
09 Jun 2022 //
FIERCEBIOTECH
Aldeyra Tx Designates Schirmer Test in PIII TRANQUILITY-2 Trial of Reproxalap
24 May 2022 //
BUSINESSWIRE
Aldeyra Publishes Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model
01 Feb 2022 //
BUSINESSWIRE
Aldeyra Announces Positive Top-Line Data from Phase 2 Trial of Reproxalap
11 Jan 2022 //
BUSINESSWIRE
Aldeyra shares tank after late-stage failure in dry eye disease; still files NDA
22 Dec 2021 //
ENDPTS
Aldeyra Announces Top-Line Results from Phase 3 Trial in Dry Eye Disease
20 Dec 2021 //
BUSINESSWIRE
Aldeyra concludes enrolment in Phase III dry eye disease treatment trial
10 Nov 2021 //
CLINICALTRIALSARENA
Aldeyra dry eye drug helps with redness, misses secondary goals
03 Nov 2021 //
FIERCEBIOTECH
Aldeyra Announces First Patient Enrolled in the Ph3 Trial of Reproxalap
08 Dec 2020 //
BUSINESSWIRE
Aldeyra Announces First Patient Enrolled in the Ph3 Trial of Reproxalap
08 Dec 2020 //
BUSINESSWIRE
Aldeyra` Reproxalap Improves Allergic Eye Inflammation in Mid-Stage Trial Data
26 Oct 2020 //
FIRSTWORDPHARMA
Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic
22 Oct 2020 //
BIOSPACE
Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection
24 Mar 2020 //
BUSINESSWIRE
Aldeyra Therapeutics Announces Positive Top-Line Results
03 Dec 2019 //
BIO SPACE
Aldeyra`s eye drug fails pivotal test for rare, inflammatory disease
25 Jun 2019 //
ENDPTS
Aldeyra’s eye allergy drug sails through first phase 3 trial
27 Mar 2019 //
FIERCE BIOTECH
Bio Roundup: Amarin’s Stunner, Lung Cancer News, Data Dumps & More
28 Sep 2018 //
XCONOMY
Aldeyra has positive dry eye data — for now
27 Sep 2018 //
BIOPHARMA DIVE
